Geneva Capital Management LLC Buys 2,164 Shares of Repligen Co. (NASDAQ:RGEN)

Geneva Capital Management LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 120,167 shares of the biotechnology company’s stock after buying an additional 2,164 shares during the quarter. Geneva Capital Management LLC’s holdings in Repligen were worth $21,606,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of RGEN. Benjamin F. Edwards & Company Inc. raised its stake in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the period. Signaturefd LLC raised its position in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares during the period. Milestone Investment Advisors LLC purchased a new position in Repligen in the third quarter valued at about $61,000. Headlands Technologies LLC bought a new position in shares of Repligen during the 3rd quarter valued at approximately $75,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of Repligen by 67.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 215 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RGEN. KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. lowered their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Finally, Stifel Nicolaus increased their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Price Performance

Shares of Repligen stock traded down $0.61 on Thursday, reaching $164.89. The stock had a trading volume of 419,610 shares, compared to its average volume of 536,302. The business’s 50 day moving average is $178.64 and its two-hundred day moving average is $174.49. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a market cap of $9.21 billion, a P/E ratio of 659.56, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. As a group, research analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Insider Activity

In other Repligen news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 in the last quarter. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.